MED Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
76.4M
+0.4%
76.0M
+1.3%
75.1M
-16.0%
89.4M
-15.3%
105.6M
Cost of Revenue
23.0M
-5.4%
24.3M
+5.8%
23.0M
-15.8%
27.3M
-5.7%
28.9M
Gross Profit
53.4M
+3.2%
51.8M
-0.7%
52.1M
-16.1%
62.2M
-18.9%
76.6M
Operating Expenses
57.7M
+4.9%
55.1M
-8.2%
59.9M
-9.5%
66.2M
-14.8%
77.7M
R&D
0
0
0
0
0
SG&A
57.7M
+4.9%
55.1M
-8.2%
59.9M
-9.5%
66.2M
-14.8%
77.7M
Operating Income
-4327000
-31.3%
-3295000
+57.8%
-7803000
-91.2%
-4081000
-282.8%
-1066000
EBITDA
-881000
-568.6%
188.0K
+104.3%
-4338000
-323.6%
-1024000
-134.4%
3.0M
Net Income
-3100000
-46.1%
-2122000
+88.3%
-18119000
-701.4%
-2261000
-191.2%
2.5M
EPS (Basic)
$-0.28
-47.4%
$-0.19
+88.5%
$-1.65
-685.7%
$-0.21
-191.3%
$0.23
EPS (Diluted)
$-0.28
-47.4%
$-0.19
+88.6%
$-1.66
-690.5%
$-0.21
-195.5%
$0.22
Shares (Diluted)
11.1M
+1.2%
11.0M
+0.7%
10.9M
-0.6%
11.0M
-0.6%
11.1M
Medifast (MED) โ€” Financials